Fig. 1.

Risk of basal ganglia and cerebellum diseases (diagnosis age of 21–66 years) in ADHD patients vs. non-ADHD subjects overall and for: ADHD plus (+) stimulants, ADHD plus (+) methylphenidate, and ADHD without known stimulants. Adjusted hazard ratios and 95% confidence intervals (controlling for sex, age, race/ethnicity, psychotic conditions, tobacco use, and an interaction of psychotic conditions and ADHD) are shown on a log 10 scale. Corrected P values are presented (significance level ≤0.005)